The Experts below are selected from a list of 885 Experts worldwide ranked by ideXlab platform
Mark D. Stenglein - One of the best experts on this subject based on the ideXlab platform.
-
Respiratory disease in ball pythons (Python regius) experimentally infected with ball python nidovirus.
Virology, 2018Co-Authors: Laura L. Hoon-hanks, Marylee L. Layton, Robert J. Ossiboff, John S. L. Parker, Mark D. StengleinAbstract:Abstract Circumstantial evidence has linked a new group of nidoviruses with respiratory disease in pythons, lizards, and cattle. We conducted experimental infections in ball pythons (Python regius) to test the hypothesis that ball python nidovirus (BPNV) infection results in respiratory disease. Three ball pythons were inoculated orally and intratracheally with cell culture isolated BPNV and two were sham inoculated. Antemortem choanal, oroesophageal, and cloacal swabs and postmortem tissues of infected snakes were positive for viral RNA, protein, and infectious virus by qRT-PCR, immunohistochemistry, western blot and virus isolation. Clinical signs included oral mucosal reddening, abundant mucus secretions, open-mouthed breathing, and anorexia. Histologic lesions included chronic-active mucinous rhinitis, stomatitis, Tracheitis, esophagitis and proliferative interstitial pneumonia. Control snakes remained negative and free of clinical signs throughout the experiment. Our findings establish a causal relationship between nidovirus infection and respiratory disease in ball pythons and shed light on disease progression and transmission.
Xiao-dong Luo - One of the best experts on this subject based on the ideXlab platform.
-
pharmacological evaluation of alstonia scholaris anti tussive anti asthmatic and expectorant activities
Journal of Ethnopharmacology, 2010Co-Authors: Jianhua Shang, Xiang-hai Cai, Tao Feng, Yunli Zhao, Xiao-dong LuoAbstract:Ethnopharmacological relevance: Alstonia scholaris (Apocynaceae) was documented as an effective herb for the treatment of chronic respiratory diseases in "dai" ethnopharmacy historically, and its leaf crude extract, used for releasing Tracheitis and cold symptom, was approved to be a commercial formulation by State Food and Drugs Administration of China (SFDA).
-
pharmacological evaluation of alstonia scholaris anti inflammatory and analgesic effects
Journal of Ethnopharmacology, 2010Co-Authors: Jianhua Shang, Xiang-hai Cai, Tao Feng, Yunli Zhao, Jingkun Wang, Luyong Zhang, Ming Yan, Xiao-dong LuoAbstract:Ethnopharmacological relevance: Alstonia scholaris (Apocynaceae) has been historically used in "dai" ethnopharmacy to treat chronic respiratory diseases. The leaf extract, developed as a commercially available traditional Chinese medicine, used to release Tracheitis and cold symptom, has also been prescribed in hospitals and sold over the counter in drug stores.
Amilcare S Rottoli - One of the best experts on this subject based on the ideXlab platform.
-
Positive clinical outcomes derived from using Streptococcus salivarius K12 to prevent streptococcal pharyngotonsillitis in children: a pilot investigation.
Drug healthcare and patient safety, 2016Co-Authors: Francesco Di Pierro, Alberto Zanvit, Maria Colombo, Amilcare S RottoliAbstract:Background Streptococcus salivarius K12 (BLIS K12®) is a probiotic strain producing the bacteriocins salivaricin A2 and salivaricin B, both of which strongly antagonize the growth of Streptococcus pyogenes, the most important bacterial cause of pharyngeal infections in humans. It successfully colonizes and exhibits persistence in the oral cavity and is endowed with an excellent safety profile. Previous observations of a small group of children indicated that the use of BLIS K12 could also reduce the occurrence of viral pharyngitis. The present study focused on a further evaluation of the role of BLIS K12 in the control of pediatric streptococcal disease and moreover whether its use could also help provide protection against various nonstreptococcal infections. Methods In total, 48 children with a recent history of recurrent pharyngeal streptococcal disease were enrolled in the treated group. The control group comprised 76 children known to have had a very low recent occurrence of oral streptococcal disease. The treated children were given BLIS K12 daily for 90 days. The number of episodes of streptococcal pharyngotonsillitis, Tracheitis, viral pharyngitis, rhinitis, flu, laryngitis, acute otitis media, enteritis, and stomatitis was recorded during probiotic treatment and for a follow-up period of 9 months, and this was compared with the episodes of the control group over the corresponding period. Results Compared with the pretreatment time period, 2013, a 90% reduction of streptococcal pharyngeal disease was observed in 2014; compared with untreated children, a statistically significant reduction of all of the other disease conditions assessed, other than stomatitis, was detected in the probiotic-treated children. Conclusion In agreement with previous findings, in the present study, it was found that the daily use of BLIS K12 has been associated with a concurrent and persisting reduction in the occurrence of pharyngeal, recurrent, streptococcal disease. Moreover, the benefits to children may also extend to a reduction of nonstreptococcal diseases, including Tracheitis, viral pharyngitis, rhinitis, flu, laryngitis, acute otitis media, and enteritis.
Laura L. Hoon-hanks - One of the best experts on this subject based on the ideXlab platform.
-
Respiratory disease in ball pythons (Python regius) experimentally infected with ball python nidovirus.
Virology, 2018Co-Authors: Laura L. Hoon-hanks, Marylee L. Layton, Robert J. Ossiboff, John S. L. Parker, Mark D. StengleinAbstract:Abstract Circumstantial evidence has linked a new group of nidoviruses with respiratory disease in pythons, lizards, and cattle. We conducted experimental infections in ball pythons (Python regius) to test the hypothesis that ball python nidovirus (BPNV) infection results in respiratory disease. Three ball pythons were inoculated orally and intratracheally with cell culture isolated BPNV and two were sham inoculated. Antemortem choanal, oroesophageal, and cloacal swabs and postmortem tissues of infected snakes were positive for viral RNA, protein, and infectious virus by qRT-PCR, immunohistochemistry, western blot and virus isolation. Clinical signs included oral mucosal reddening, abundant mucus secretions, open-mouthed breathing, and anorexia. Histologic lesions included chronic-active mucinous rhinitis, stomatitis, Tracheitis, esophagitis and proliferative interstitial pneumonia. Control snakes remained negative and free of clinical signs throughout the experiment. Our findings establish a causal relationship between nidovirus infection and respiratory disease in ball pythons and shed light on disease progression and transmission.
Jianhua Shang - One of the best experts on this subject based on the ideXlab platform.
-
pharmacological evaluation of alstonia scholaris anti tussive anti asthmatic and expectorant activities
Journal of Ethnopharmacology, 2010Co-Authors: Jianhua Shang, Xiang-hai Cai, Tao Feng, Yunli Zhao, Xiao-dong LuoAbstract:Ethnopharmacological relevance: Alstonia scholaris (Apocynaceae) was documented as an effective herb for the treatment of chronic respiratory diseases in "dai" ethnopharmacy historically, and its leaf crude extract, used for releasing Tracheitis and cold symptom, was approved to be a commercial formulation by State Food and Drugs Administration of China (SFDA).
-
pharmacological evaluation of alstonia scholaris anti inflammatory and analgesic effects
Journal of Ethnopharmacology, 2010Co-Authors: Jianhua Shang, Xiang-hai Cai, Tao Feng, Yunli Zhao, Jingkun Wang, Luyong Zhang, Ming Yan, Xiao-dong LuoAbstract:Ethnopharmacological relevance: Alstonia scholaris (Apocynaceae) has been historically used in "dai" ethnopharmacy to treat chronic respiratory diseases. The leaf extract, developed as a commercially available traditional Chinese medicine, used to release Tracheitis and cold symptom, has also been prescribed in hospitals and sold over the counter in drug stores.